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HPV16 oncogene expression levels during early cervical
carcinogenesis are determined by the balance of epigenetic
chromatin modiﬁcations at the integrated virus genome
IJ Groves, ELA Knight, QY Ang, CG Scarpini and N Coleman
In cervical squamous cell carcinomas, high-risk human papillomavirus (HRHPV) DNA is usually integrated into host chromosomes.
Multiple integration events are thought to be present within the cells of a polyclonal premalignant lesion and the features that
underpin clonal selection of one particular integrant remain poorly understood. We previously used the W12 model system to
generate a panel of cervical keratinocyte clones, derived from cells of a low-grade premalignant lesion naturally infected with the
major HRHPV type, HPV16. The cells were isolated regardless of their selective advantage and differed only by the site of HPV16
integration into the host genome. We used this resource to test the hypothesis that levels of HPV16 E6/E7 oncogene expression in
premalignant cells are regulated epigenetically. We performed a comprehensive analysis of the epigenetic landscape of the
integrated HPV16 DNA in selected clones, in which levels of virus oncogene expression per DNA template varied ~ 6.6-fold. Across
the cells examined, higher levels of virus expression per template were associated with more open chromatin at the HPV16 long
control region, together with greater loading of chromatin remodelling enzymes and lower nucleosome occupancy. There were
higher levels of histone post-translational modiﬁcation hallmarks of transcriptionally active chromatin and lower levels of repressive
hallmarks. There was greater abundance of the active/elongating form of the RNA polymerase-II enzyme (RNAPII-Ser2P), together
with CDK9, the component of positive transcription elongation factor b complex responsible for Ser2 phosphorylation. The changes
observed were functionally signiﬁcant, as cells with higher HPV16 expression per template showed greater sensitivity to depletion
and/or inhibition of histone acetyltransferases and CDK9 and less sensitivity to histone deacetylase inhibition. We conclude that
virus gene expression per template following HPV16 integration is determined through multiple layers of epigenetic regulation,
which are likely to contribute to selection of individual cells during cervical carcinogenesis.
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INTRODUCTION
Infection with high-risk human papillomavirus (HRHPV) is respon-
sible for over 600 000 new cancers per annum, including over
500 000 carcinomas of the cervix.1 The majority of cervical
malignancies are squamous cell carcinomas (SCCs), which arise
from a mixed population of HRHPV-infected cells by clonal
selection of cells with the greatest competitive growth
advantage.2,3 In ~ 85% of cervical SCCs the selected cells contain
HRHPV DNA that is integrated into host chromosomes. In the
remaining ~ 15% of cases the virus genome remains in the extra-
chromosomal (episomal) state, as is also seen in the normal virus
lifecycle.4–6
In the squamous epithelial lesions that result from productive
HRHPV infections, there are ~ 100 virus episome copies in each
basal layer cell.7,8 In the lower cell layers, the necessary expression
of the HRHPV early genes E6 and E7 occurs through transcriptional
initiation at the virus early promoter (p97 in the case of the major
HRHPV, HPV16), while cell maturation is associated with activation
of the virus late promoter (p670 for HPV16) and expression of late
virus genes. These events are linked to changes in transcription
factor binding and altered chromatin structure, based on histone
post-translational modiﬁcations (PTMs) at nucleosomes associated
with the HRHPV genome.3,9–13
Integration of HRHPV genomes is thought to occur in
premalignant squamous intraepithelial lesions (SILs). The prob-
ability of integration increases with time14 and multiple integra-
tion events are thought to be present across the cells of a
polyclonal SIL. However, relatively little is known about how
particular cells containing integrated HPV gain a growth
advantage over other cells with HPV integrated elsewhere in the
genome. Notably, the signiﬁcance of virus transcriptional dereg-
ulation in individual integrants during these early events in
cervical carcinogenesis is poorly understood. Most studies to date
have concerned the end point of the clonal selection process, by
focusing on the virus integrants seen in the SCC cells themselves,
and have not addressed the dynamic changes that underpin
progression from SILs to carcinomas. It is difﬁcult to study such
processes by cross-sectional analysis of clinical samples, as the key
events that precede clonal selection early in cervical carcinogen-
esis occur in the basal epithelial cells of low-grade SILs (LSILs),4,15
which would need to be isolated by tissue micro-dissection.
A more informative approach has been to study experimental
in vitro models, including W12.
The W12 system was developed from a polyclonal culture of
cervical squamous cells (keratinocytes) naturally infected with
HPV16, which were derived by explant culture of a cervical LSIL.7
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At early passages, these ‘parental’ W12 cells are phenotypically
and genetically stable. They allow maintenance of HPV16
episomes at ~ 100 copies per cell and recapitulate an LSIL in
three-dimensional organotypic culture. Following long-term cul-
ture of W12, however, the cells lose these properties and closely
mirror the virus and host events associated with cervical
carcinogenesis in vivo, with phenotypic progression of the
reformed epithelia to high-grade SIL and then SCC.4 These events
may be associated with deregulation of episome numbers and
transcriptional control (e.g. W12 series 4 and W12E cells).2,6 More
typically, however, there is a change in the virus physical state
from episomal to integrated, due to loss of trans-repressive
episomes and emergence of a clonal population containing the
HPV16 integration event that confers the greatest growth
advantage.16 In different W12 series, different integration sites
are seen in the selected cells.16
We previously used limiting dilution cloning of polyclonal
parental W12 cells at early passage, to sample the range of
integration events that exists prior to episome clearance and
integrant emergence.14 The cells were selected under non-
competitive conditions, allowing isolation of clones regardless of
whether they had a selective advantage in mixed cell populations.
By this method, we derived a series of clones from an identical
genetic background that differed only by the site of HPV16
integration into the host genome. The large majority of clones
showed no evidence of full-length HPV16 concatemerisation17
and were therefore so called type I integrants.2 Several clones
contained multiple copies of the E6/E7 oncogenes, consistent with
local DNA rearrangements following integration. At the early
passages examined (i.e. prior to clonal evolution events), all clones
recapitulated a premalignant SIL phenotype in organotypic tissue
culture, with no evidence of invasiveness.17
The W12 clones therefore represent a unique system to
examine the host and virus factors that determine selection of a
particular HPV16 integrant from the range that exists in a typical
polyclonal population of premalignant cervical keratinocytes.
Across 17 representative clones analysed, levels of HPV16 E6
and E7 transcripts per cell varied by ~ 6-fold and correlated
closely. Only seven of the clones analysed (41%) showed
signiﬁcantly greater expression of HPV16 E6 and E7 than the
episome-containing LSIL-like cells from which they were derived,
indicating that HPV integration per se does not necessarily lead to
increased levels of virus oncogenes per cell.17 Interestingly, levels
of E6/E7 transcript per DNA template across the clones varied by
~ 16-fold.17
In the present study, we used the W12 clones to investigate
how different HPV16 integration events in basal-type premalig-
nant cervical keratinocytes lead to different levels of virus
oncogene expression. In order to provide a tractable system for
our experiments, we chose cells without full-length HPV16
concatemerisation and with four or less copies of integrated virus
DNA per cell. Of the ﬁve such clones available, two (F and A5)
showed high levels of E6/E7 expression per template, two (D2 and
H) showed medium levels and one (G2) showed low levels, with
~ 6.6-fold variation in expression levels across the ﬁve clones
(Table 1). In our previous preliminary analysis of a restricted
sequence of the HPV16 genome in the ﬁve clones,17 we found
that levels of HPV16 expression per template were associated with
different distributions of a selected small number of histone
PTMs.17,18 We therefore hypothesised that variation in levels of
expression per DNA template following HPV16 integration were
due to epigenetic differences in the virus chromatin. We used the
W12 clones to undertake a detailed and extensive analysis of the
epigenetic landscape on the integrated HPV16 genome, focussing
on the relationships between virus oncogene expression per
template and chromatin accessibility, histone PTMs and activity of
RNA polymerase-II (RNAPII).
RESULTS
HPV16 oncogene expression per template associates with
accessibility of virus chromatin
No mutations were seen in any of the ﬁve W12 clones following
PCR ampliﬁcation and sequencing of the HPV16 long control
region (LCR) (data not shown). By formaldehyde-assisted isolation
of regulatory elements, enrichment of open chromatin (i.e. with
lower nucleosome occupancy) at the HPV16 LCR and early
promoter was greatest in cells with high levels of virus gene
expression per template (F and A5) and showed progressive
reductions through cells with medium expression per template
(D2 and H) to cells with low expression per template (G2)
(Figure 1a). The positions of nucleosomes, as indicated by
nucleosome occupancy and methylome sequencing, were similar
across all clones and usually spaced 150–200 bp apart. These
positions were indicated by low levels of exogenously applied
GpC methylation. However, clones with high expression per
template showed greater amounts of exogenously applied GpC
methylation at the early promoter and directly after the
transcription start site (Figure 1b), indicating lower average
occupancy of the nucleosomes and therefore greater chromatin
accessibility in this region. Cells with higher virus expression levels
per template also showed a greater abundance of the ATP-
dependent chromatin remodelling enzymes BRG1 and INI1 across
the virus genome (Figures 1c and d), in keeping with greater
openness/accessibility of the HPV16 chromatin in these cells. Both
enzymes were most abundant over the virus early region,
including the early and late promoters. There was a striking peak
Table 1. Details of the W12 clones studied
Clone Integration site Ploidy HPV16 gene copy number HPV16 E6/E7 expression
per template
Expression per
template category
E6 E7 Mean E6/E7 E2-5′ E2-3′
F 4q13.3 2N 1 1 1 1 1 248.6 (±31.8) HIGH
A5 8p11.21 2N 1 1 1 1 1 215.6 (±14.9)
D2 18q21.2 2N 3 4 4 0 3 118.5 (±12.0) MEDIUM
H 4q21.23 2N 1 1 1 0 1 100.1 (±12.4)
G2 21q22.1 2N 3 3 3 3 0 37.5 (±4.2) LOW
All virus gene copy numbers were adjusted for cell ploidy and rounded to the nearest whole number. Levels of HPV16 E6 and E7 transcripts per template were
referenced individually to low passage episome-containing W12 cells (W12 Series6 p11) and mean values (± s.e.m.) were determined from three biological
replicates. Clone G2 showed three different virus–host junction transcripts by RNA-sequencing and clone D2 showed four different virus–host junction
transcripts (data not shown). All clones tested (F, A5, D2 and G2) reformed an LSIL in organotypic tissue culture.
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Figure 1. Levels of HPV16 transcription per template associate with virus genome accessibility. (a) In each graph the y-axis shows fold enrichment of
open chromatin across the HPV16 genome, as determined by FAIRE using three biological replicates. Values were normalised to the efﬁciency of
enrichment, as determined by the ratio of GAPDH promoter to GAPDH open reading frame qPCR. The x-axis and underlying schematic show the
region of the HPV16 genome analysed. The panels show data for the clones in which transcription levels per template were high, medium (MED) or
low. (b) Virus genome occupancy by nucleosomes or other DNA-binding proteins, as determined by NOMe sequencing using four biological
replicates. Regions with a lower rate of occupancy are indicated by higher levels of exogenously applied GpC methylation. The degree of GpC
methylation is shown as a heat map (see key), with circles at individual nucleotide positions. (c, d) Association of chromatin remodelling enzymes
BRG1 and INI1 with the integrated HPV16 genome across the cell lines. The y-axis shows relative levels of enrichment of BRG1 (c) and INI1 (d),
derived from three biological replicates in each case and normalised to host control target regions (see Supplementary Table S1). The x-axis and
underlying schematic show the region of the HPV16 genome analysed. In all panels, data for each of the ﬁve clones are colour coded according to
the key at the foot of the ﬁgure. This code is maintained in all subsequent ﬁgures. In all panels, bars=mean± s.e.m. Abbreviation: FAIRE,
formaldehyde-assisted isolation of regulatory element; NOMe, nucleosome occupancy and methylation.
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of INI1 abundance at the early promoter and transcription start
site in clone F.
High HPV16 expression requires activating chromatin marks
We next quantiﬁed levels of histone PTMs on the integrated virus
chromatin. Higher virus expression per template was associated
with greater levels of histone 3 lysine 4 tri-methylation (H3K4me3),
a hallmark of transcriptional activity. We extended our previous
observations17 by showing that this mark was only present
downstream of the HPV16 early promoter and was absent from
the late region (Figure 2a). Key enzymatic writers of the mark,
SETD1A and MLL1, were also more abundant at the virus genome
in cells with higher expression per template, with consistent
enrichment at the LCR and early promoter (Figures 2b and c).
There was more variable enrichment over the late and early
regions, with higher levels of SETD1A in clones A5 and D2 and
MLL1 in A5. The cells with high expression per template also
showed enrichment of histone PTMs associated with gene
enhancer/promoter regions, with strong enrichment of
H3K4me1 across the entire virus genome, including the late
genes (Figure 2d), and greater abundance of H3K27ac, predomi-
nantly at the LCR and early genes (Figure 2e).
Conversely, lower levels of expression per template were
associated with higher levels of repressive histone PTMs, namely
di-methylation of histone 3 lysines 9 and 27 (H3K9me2 and
H3K27me2) (Supplementary Figures S1A and C). However, there
was very little enrichment of tri-methylated forms of these
histones (H3K9me3 and H3K27me3) at any of the integrated
HPV16 genomes (Supplementary Figures S1B and D). The cells
with lower expression also showed higher levels of endogenous
CpG DNA methylation across the HPV16 genomic region analysed
(nt 6731 to 1287) (Figure 3a). There was a prominent peak of DNA
methylation at the LCR in G2, the only clone showing low
expression per template (Figure 3b). Levels of methylation at L1
were variable, including between clones with similar levels of virus
gene expression per template (Figure 3b).
HPV16 transcription per template associates with histone
methylation modifying enzymes
Higher virus expression per template was associated with higher
levels of general histone 3 acetylation (H3ac) (Figure 4a), together
with greater abundance of the histone acetyltransferases (HATs)
p300 and TIP60, across the entire HPV16 genome (Figures 4b and
c). The abundance of these enzymes at the HPV16 genome showed
no relation to total levels in the cells, indicating speciﬁc loading
onto the virus chromatin (Supplementary Figure S2). High levels of
p300 across the HPV16 genome were associated with high overall
abundance of cJun (Supplementary Figure S3A), which can act as a
p300 recruiter protein.19 However, there was no close association
between levels of p300 and cJun at individual sites on the virus
genome. Levels of TIP60 were not associated with those of its
potential recruiter protein YY1 (Supplementary Figure S3B), but did
associate closely with levels of H3K4me1 (Figure 2d).
We tested the functional signiﬁcance of HAT recruitment in
determining levels of HPV16 transcript expression. We inhibited
p300 or TIP60 in the cells with the highest and lowest levels of
virus early gene expression per template (clones F and G2,
respectively) (Figures 4d–k). We did not examine post-
transcriptional effects on HPV16 oncoprotein levels in these
experiments. We observed signiﬁcantly greater reductions in
E6/E7 transcript levels in clone F vs G2 when p300 was depleted
using siRNA (Figure 4h) or speciﬁcally inhibited using C646
(Figure 4j) and when TIP60 was depleted using siRNAs (Figure 4i)
or speciﬁcally inhibited using MG149 (Figure 4k).
Mirroring these observations with HATs, cells with lower virus
transcript levels per template showed higher abundance of
histone deacetylase 1 (HDAC1) (Figure 5a). In the absence of
speciﬁc siRNAs targeting HDAC1, we used the class I/II HDAC-
speciﬁc small-molecule inhibitor Trichostatin-A. After 16 h of
treatment, this produced signiﬁcantly greater increases in HPV16
E6/E7 transcript levels in clone G2 than in clone F (Figure 5b).
Transcript levels per template associate with active RNAPII,
determined by P-TEFb (CDK9)
There were no differences across the clones in the overall amounts
of RNAPII associated with the HPV16 genome (Figure 6a).
However, cells with lower virus expression per template showed
higher amounts of the poised/paused or stalled form of RNAPII,
Ser5P, across the early genes (Figure 6b). Conversely, cells with
higher expression per template showed greater amounts of the
active/elongating form of RNAPII, Ser2P, across the virus LCR and
early genes (Figure 6c), together with higher levels of histone 3
lysine 36 tri-methylation (H3K36me3), a histone PTM associated
with transcriptional elongation (Figure 6d). There were also higher
levels of the positive transcription elongation factor b (P-TEFb)
complex kinase CDK9 (Figure 7a), which is responsible for
phosphorylation of the RNAPII C-terminal domain at Ser2.
Depletion of CDK9 (Figures 7b and c) produced signiﬁcantly
greater reductions in E6/E7 transcript levels in clone F (higher
expression per template) than in clone G2 (lower expression per
template) (Figure 7d) (F vs G2 Po0.001).
We next investigated the consequences of inhibiting CDK9
function in high expressing clone F cells. As the chromatin yield
from siRNA experiments was too low, we used the small-molecule
inhibitor Flavopiridol, which caused 87% reduction in E6/E7
transcript levels (Supplementary Figure S4A). Similar effects were
also seen using other small inhibitors with predominant speciﬁcity
for CDK9 (Supplementary Figure S4A). While Flavopiridol pro-
duced no change in overall levels of CDK9 recruitment at the
HPV16 genome (Figure 8a), there were reduced levels of total
RNAPII, particularly downstream of the virus early promoter
(Figure 8b). There was also less elongating RNAPII-Ser2P down-
stream of the transcription start site, with evidence of redistribu-
tion to the LCR/early promoter region (Figure 8c). In addition, the
LCR and early genes showed striking decreases in the histone PTM
mark of transcriptional activation, H3K4me3 (Figure 8d), mirrored
by increases in the mark of constitutive heterochromatin and
transcriptional repression, H3K9me2 (Figure 8e).
Similar observations to those made in clone F were seen in the
cervical SCC cell line SiHa. Indeed, the CDK9 inhibitors (including
Flavopiridol) produced greater reductions in E6/E7 expression in SiHa
than in clone F (95%) (Supplementary Figure S4A), while Flavopiridol
led to more pronounced shifts in epigenetic marks and reduced
RNAPII-Ser2P levels (Figures 8f–j). Transcript levels in SiHa reduced by
480% over the ﬁrst 8 h of Flavopiridol treatment (Supplementary
Figure S4B), consistent with profound transcriptional shut off of the
integrated HPV16 DNA. These changes were associated with
complete inhibition of cell growth (Supplementary Figure S4C).
DISCUSSION
The W12 cell clones represent a unique resource that has enabled
us to study the factors associated with the large differences in
virus oncogene expression per template observed following
natural HPV16 integration events in premalignant basal cervical
keratinocytes. We focussed on ﬁve clones from the same genetic
background, in which HPV16 was integrated at low copy number
without full-length virus concatemers. The cells were studied at a
very early stage after cloning, when levels of E6/E7 varied by
~ 6.6-fold but the cells had not shown the effects of HPV16
oncoprotein-driven genomic instability and still recapitulated an
LSIL phenotype in organotypic tissue culture. Our ﬁndings indicate
that levels of HPV16 expression following integration are
determined through multiple layers of epigenetic regulation.
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Figure 2. Associations with active histone PTMs and modifying enzymes. Levels of association of the H3K4me3 histone PTM (derived from four
biological replicates) (a) and the associated histone-modifying enzymes SETD1A (three replicates) (b) and MLL1 (four replicates) (c); as well as
the transcriptional enhancer marks H3K4me1 (three replicates) (d) and H3K27ac (two replicates) (e). In each graph, the y-axis shows the
relative levels of enrichment, normalised to host control target regions (see Supplementary Table S1). The x-axis and underlying schematic
show the region of the HPV16 genome analysed. In all panels, data are colour coded according to the key at the foot of the ﬁgure.
Bars=mean± s.e.m.
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Our initial data showed that high virus expression per template
was associated with open chromatin at the HPV16 LCR, together
with greater loading of chromatin remodelling enzymes and less
nucleosome occupancy across the HPV16 early promoter and the
oncogenes E6/E7. Together, these changes would be expected to
increase template accessibility for the cellular transcriptional
machinery, enabling transcriptional activation and RNAPII
elongation. The reasons for the relative abundance of BRG1 and
INI1 over the virus early region are not certain but may be related
to the ability of these enzymes to orchestrate long-range
interactions between promoter-enhancer regions.20,21
Levels of HPV16 expression per template were positively
associated with higher abundance of histone PTMs that marked
transcriptionally active chromatin, together with the cognate
Figure 3. Associations with CpG DNA methylation. (a) Cumulative levels of endogenous CpG DNA methylation across the integrated HPV16
genomes, derived from three biological replicates. The coloured bars in each stack correspond to individual CpG sites. The order of the bars in
each stack (from bottom to top) corresponds to the order of the CpG coordinates (from left to right) in the genome map at the base of the
panel. P-values (Student’s t-test): **Po0.01, ***Po0.001. (b) Percentage of endogenous DNA methylation at CpG dinucleotides across the
HPV16 genome (y-axis). The x-axis and underlying schematic show the region of the HPV16 genome analysed. Bars=mean+s.e.m.
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Figure 4. Associations with histone acetylation and HAT abundance/activity. (a–c) Levels of the H3ac histone PTM (derived from three
biological replicates) (a) and the associated HAT enzymes p300 (three replicates) (b) and TIP60 (three replicates) (c). In each graph, the y-axis
shows the relative levels of enrichment, normalised to host control target regions (see Supplementary Table S1). The x-axis and underlying
schematic show the region of the HPV16 genome analysed. In all panels, data are colour coded according to the key beneath panel c.
(d–k) Depletion/inhibition in clones F and G2 of HAT enzymes p300 (upper row) and TIP60 (lower row). The panels show levels of depletion of
target mRNAs (d, e), target protein (f, g) and HPV16 E6/E7 transcripts (h, i) in siRNA-treated vs NTC-treated cells, together with HPV16 E6/E7
transcript levels in cells treated with speciﬁc small-molecule inhibitors, vs cells treated with vehicle only (j, k). All data for p300 were derived
from four biological replicates and all data for TIP60 from six biological replicates. Each western blot used protein samples from all replicate
experiments combined. Bars=mean± s.e.m. P-values (Student’s t-test): *Po0.05, **Po0.01, ***Po0.001, NS=not signiﬁcant. Abbreviation:
NTC, non-targeting control.
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writer enzymes. The presence of the transcriptional activation
mark H3K4me3 was associated with consistent enrichment for the
H3K4 methylases SETD1A and MLL1 at the LCR, where the
enzymes would be recruited to the activating RNAPII complex.
This observation is paralleled by evidence that a speciﬁc isoform
of MLL5 (MLL5β) is recruited via a distal AP1 site at the HPV18 LCR
and is necessary for virus oncogene expression.22 The reasons for
the different distributions of H3K4me3 and H4K4me1 are unclear
and may be related to the relative distribution or balance of the
H3K4 methylases and their cofactors.23
Expression levels per template were negatively associated with
repressive heterochromatin marks and with overall levels of
endogenous CpG DNA methylation. In the type I HPV16 integrants
studied here, there was no clear relationship between virus
expression per template and L1 methylation. At present, there is
considerable interest in using HRHPV methylation as a clinical
diagnostic test, for example to triage cytology samples.24 Our data
indicate a need for further investigations of the associations
between HRHPV L1 methylation and virus parameters (e.g.
physical state, presence or absence of full-length concatemers,
levels of early gene expression per template), in order to
understand better the potentially complex relationship between
L1 methylation and cervical neoplastic progression.
Interestingly, the repressive heterochromatin marks H3K9me2
and H3K27me2 were present at much greater overall abundance
than the equivalent tri-methyl marks H3K9me3 and H3K27me3.
Previous work has shown a global reduction in H3K27me3 in
HRHPV-infected cells, caused by virus-driven upregulation of
H3K27 demethylases KDM6A and KDM6B, and inhibition of the
polycomb repressive complex 2, the writer of the H3K27me3
mark.25,26 The absence of these heterochromatic tri-methyl
marks is also consistent with chromatin immunoprecipitation
sequencing data from the HPV18-positive cervical adenocarci-
noma cell line HeLa27 and analyses of undifferentiated and
differentiated squamous epithelial cells containing HPV31 episo-
mal genomes.11 Indeed, for naturally occurring HRHPV integrants
(as opposed to those generated experimentally) signiﬁcant levels
of heterochromatic marks, including H4K20me3, have only been
reported in CaSki cervical SCC cells, in which there is an unusually
high number of integrated HPV16 genomes (~600 copies).28
Virus expression per template was associated with histone
acetylation at the integrated HPV16 genomes, consistent with our
previous ﬁndings in episome-associated cervical carcinogenesis6
and with observations using genetically modiﬁed HPV16
templates.29 Histone acetylation associated positively with levels
of both HATs examined, p300 and TIP60. High levels of p300 were
associated with greater overall abundance of cJun, a potential
component of the AP1 complex, which is a possible mechanism of
p300 recruitment. While it has previously been shown that p300
can activate HPV gene expression,19,30,31 our data demonstrate a
functional, dose-dependent relationship between levels of p300
and HPV16 gene expression, as cells with high virus expression per
template showed signiﬁcantly greater sensitivity to p300 deple-
tion or inhibition than those with low expression per template.
Similar observations were made when inhibiting TIP60. Interest-
ingly, there is evidence that TIP60 is a transcriptional repressor at
the HPV18 early enhancer/promoter and can be targeted for
degradation by the HPV18 E6 protein.31,32 Inhibition using MG149
also indicated an activating role for TIP60 in episome-containing
parental W12 cells (data not shown), despite the presence of E2
protein, which has been shown to organise TIP60-mediated
repression of the HPV18 LCR.33 Therefore, the function of TIP60 at
HPV16 genomes is not obviously dictated by template structure.
Figure 5. Associations with HDAC abundance/activity. (a) Levels of association of HDAC1 enzyme. The y-axis shows the relative levels of
enrichment, derived from two biological replicates and normalised to host control target regions (see Supplementary Table S1). The x-axis and
underlying schematic show the region of the HPV16 genome analysed. (b) Changes in HPV16 E6/E7 transcript levels following type I/type II
HDAC inhibition with TSA in clones F and G2, derived from three biological replicates. Bars=mean± s.e.m. P-values (Student’s t-test):
*Po0.05.
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The reasons for the disparate observations concerning TIP60
function are unclear. The mechanism of TIP60 recruitment may be
relevant, as we observed no overall association between levels of
TIP60 and YY1 in W12 cells, whereas YY1 was found at the
integrated HPV18 genome in HeLa cells, where TIP60 is
repressive.31 In the absence of YY1, TIP60 can be recruited to
chromatin via activated RNAPII-Ser2P itself34 and by various other
transcription factors including E2F1, MYC, MAX and MXI1, all of
which have been found at the HPV18 LCR.27 Indeed, increased
TIP60 recruitment to the hTERT promoter, likely through MYC
interaction, was seen in human foreskin keratinocytes expressing
HPV16 E6 protein.35 TIP60 has also been shown to interact directly
with chromatin through its chromodomain. This can occur via the
repressive mark H3K9me3 at DNA double-strand breaks36 but also
via the active marks H3K4me3 (enabling TIP60 to act as a histone
code reader/translator)37 and H3K4me1.38 The latter, when
combined with H3K27ac, is an indicator of active enhancers.39 In
the W12 cells with high virus expression per template, these marks
Figure 6. Associations with RNAPII and H3K36me3. Levels of association of total RNAPII (derived from three biological replicates) (a), RNAPII-
Ser5P (poised/paused) (three replicates) (b), RNAPII-Ser2P (active/elongating) (three replicates) (c) and H3K36me3 (two replicates) (d). In each
graph, the y-axis shows the relative levels of enrichment, normalised to host control target regions (see Supplementary Table S1). The x-axis
and underlying schematic show the region of the HPV16 genome analysed. In all panels, data are colour coded according to the key at the
foot of the ﬁgure. Bars=mean± s.e.m.
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were present, together with p300, at the integrated HPV16 LCR,
which therefore appears to be acting as a canonical enhancer of
transcription. Interestingly, such marks were also present over the
virus late gene region, which, when out of the context of the
episomal genome, may augment integrated HPV16 gene
expression.
The differences in HAT recruitment between the clones were
mirrored by differences in HDAC1 abundance at the HPV16
genome. HDAC1 levels were greater in cells with less virus gene
expression per template, which showed signiﬁcantly greater
increases in transcript levels following HDAC inhibition. However,
HDAC1 was detectable at the virus genome in all clones and all
showed increased gene expression levels following HDAC
inhibition with TSA over a relatively long duration of 16 h. These
observations are consistent with data describing the necessity for
HDAC presence at gene promoter regions, in order to allow
resetting of histone acetylation during the dynamic turnover of
these marks that accompanies RNAPII progression.34,40
While virus expression per template showed no association with
overall levels of RNAPII at the HPV16 genome, there was an
association with levels of the active/elongating form of the
enzyme (RNAPII-Ser2P), together with those of CDK9, the
component of P-TEFb responsible for phosphorylating Ser2 of
the RNAPII C-terminal domain. The CDK9 enzyme was functionally
signiﬁcant, as evidenced by a greater sensitivity to depletion in
cells with higher HPV16 gene expression per template. We also
observed striking changes in the distribution of RNAPII and
chromatin marks following treatment with Flavopiridol. While this
small molecule can inhibit multiple CDKs and affect cell cycle
progression, its major mode of action is considered to be
inhibition of CDK9.41,42 The importance of P-TEFb/CDK9 in
transcription of integrated HPV16 supports observations for other
viruses. For example, CDK9 is necessary to relieve RNAPII pausing
at the Epstein-Barr virus C promoter and drive transcription of
polycistronic virus mRNAs,43 while P-TEFb is required for Tat-
driven transcriptional elongation at the human immunodeﬁciency
virus (HIV) long terminal repeat.44
Together, our data are consistent with the model shown in
Figure 9. Integrated HPV16 templates showing higher levels of
oncogene expression are associated with more accessible DNA,
via the action of chromatin remodellers. This accessibility leads to
the recruitment of activating histone-modifying enzymes, either
directly or via transcription factors. In turn, these enzymes
methylate and acetylate histone tails, so that the recruitment
and activation of RNAPII can occur through activating complexes
such as P-TEFb. While the integrated templates with lower
expression levels are still able to activate RNAPII, there is a shift
in the balance of activating and repressing enzymes that affects
gene expression levels. In future work, it will be important to study
the mechanisms by which initial virus template accessibility is
determined, including whether HPV16 acquires the features of the
host chromatin at integration sites. The W12 system will allow
detailed dissection of the relative roles of virus factors, such as
those described here, and host genes in providing individual cells
with a selective advantage during the early stages of cervical
neoplastic progression.
MATERIALS AND METHODS
Cell culture
Previous publications have given detailed descriptions of the W12
system,6,16,45 including generation of the W12 cell clones.14,17 The ﬁve
clones selected for further investigation (Table 1) were episome-free and
did not express the HPV16 transcriptional regulator E2.17 All W12 cells were
Figure 7. Associations with CDK9 abundance/activity. (a) Levels of association of CDK9. The y-axis shows the relative levels of enrichment,
derived from three biological replicates and normalised to host control target regions (see Supplementary Table S1). The x-axis and underlying
schematic show the region of the HPV16 genome analysed. (b–d) Depletion of CDK9 using siRNAs, showing levels of target mRNA (b) and
protein (c), together with changes in HPV16 E6/E7 transcript levels (d), in siRNA-treated vs NTC-treated cells. All data were derived from two
biological replicates. The western blot used protein samples from both replicates combined. Bars=mean± s.e.m. P-values (Student’s t-test):
*Po0.05, **Po0.01, ***Po0.001, NS=not signiﬁcant. Abbreviation: NTC, non-targeting control.
Chromatin modiﬁcations determine HPV16 expression
IJ Groves et al
10
Oncogene (2016) 1 – 14 © 2016 Macmillan Publishers Limited
grown in monolayer culture, as described,46 in order to restrict cell
differentiation and maintain the phenotype of the basal epithelial cell
layer, the key site of HRHPV transcriptional deregulation in cervical
carcinogenesis.4,15 Cells were analysed at the lowest available passage (p)
after cloning (typically p3 to p8), in order to minimise any effects of
genomic instability caused by deregulated HPV16 oncogene expression.
We also used the HPV16-positive cervical SCC cell line SiHa,47 which
contains ~ 2 integrated virus copies and was grown as described.48
Figure 8. Effects of CDK9 inhibition. Effects of Flavopiridol in clone F (LSIL phenotype) and SiHa (SCC phenotype). Rows show levels of CDK9
(a, f), total RNAPII (b, g), RNAPII-Ser2P (active/elongating) (c, h), H3K4me3 (active) (d, i) and H3K9me2/3 (repressed) (e, j). In each graph, the
y-axis shows the relative levels of enrichment, derived from two biological replicates and normalised to host control target regions
(see Supplementary Table S1). The x-axis and underlying schematic show the region of the HPV16 genome analysed. Solid lines= control-
treated cells; dotted lines= Flavopiridol-treated cells. Bars=mean± s.e.m.
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Treatment with small-molecule inhibitors
Cells were treated for 16 h with medium supplemented with small-
molecule inhibitors, using the highest doses that did not produce cell
death over the timecourse of the experiments. The small-molecule
inhibitors used were: p300 inhibitor, C646 (SML0002; Sigma-Aldrich,
Dorset, UK; 25 μM); TIP60 inhibitor, MG149 (Axon 1785; Axon Medchem,
Groningen, Netherlands; 150 μM); HDAC inhibitor, Trichostatin-A (T1952;
Sigma-Aldrich; 400 nM); or CDK9 inhibitors, Flavopiridol (F3055; Sigma-
Aldrich; 150 nM), Roscovitine (C3249; Sigma-Aldrich; 20 μM) or DRB (D1916;
Sigma-Aldrich; 50 μM). For analysis of cell growth, cells were seeded at
5 × 104 per well and treated with Flavopiridol after 24 h. Total live cell
counts were carried out every 24 h over 5 days, using Trypan blue staining.
In all experiments, negative control cells were treated with equivalent
volumes of DMSO vehicle (vol/vol).
Gene depletion
Each target gene was depleted using human Flexitube siRNAs (Qiagen,
Crawley, UK): CDK9 (CDK9_5 SI00605066; CDK9_6 SI00605073); p300
(EP300_7 SI02626267); TIP60 (KAT5_2 SI05120304); non-targeting control
(AllStars Negative Control siRNA, 1027280). All siRNAs were used at 10 nM,
with cells being transfected at 20–30% conﬂuence using Lipofectamine
RNAiMAX (Invitrogen, Paisley, UK) as described.49,50
Quantiﬁcation of host proteins and HPV16 transcripts
Quantitative western immunoblotting was carried out as described,6,17,51
using the primary antibodies listed in Supplementary Table S1. Protein
concentrations were compared with those of the β-tubulin loading control
(Abcam, Cambridge, UK; 6ng/ml), using ImageJ software. Levels of HPV16
E6 and E7 transcripts were measured using SYBRGreen quantitative reverse
transcription–PCR (qRT–PCR), as described.17 Primers and conditions are
given in Supplementary Table S2. Relative transcript levels were
determined using the Pfafﬂ equation,52 normalised to the mean of four
housekeeping genes53 and residual levels of the target protein, then
referenced to control samples.
Chromatin immunoprecipitation
Chromatin immunoprecipitation was performed as described,6,17 using
chromatin immunoprecipitation-validated primary antibodies and appro-
priate serum/IgG negative controls (Supplementary Table S1). In contrast
to our previous assessment of a relatively limited region of the HPV16
genome, we analysed 6094 nucleotides (nt) of HPV sequence, from the L2
gene, through the LCR, to the E1 gene (nt 3936 to 2158). This genomic
region was present in all ﬁve clones, with the exception of nt 3936 to 6039
in clone H and nt 3936 to 4419 in clone D2. Primers and conditions used
for qPCR are given in Supplementary Table S3. Efﬁciency of immunopre-
cipitation of each target was normalised using control region qPCR primers
(Supplementary Table S4).
Formaldehyde-assisted isolation of regulatory elements and
nucleosome occupancy and methylome sequencing
Formaldehyde-assisted isolation of regulatory element was carried out as
described.54 Quantiﬁcation of HPV16 DNA sequences was carried out by
qPCR and normalised to the efﬁciency of enrichment, as determined by
the ratio of GAPDH promoter (open)55 to GAPDH open reading frame
(closed).43 Primers and conditions for qPCR were those in Supplementary
Tables S3 and S4. The occupancy of nucleosomes or other DNA-binding
proteins between the HPV16 early promoter and E1 gene (nt 7902 to 1012)
was assessed by nucleosome occupancy and methylome sequencing
(Active Motif, La Hulpe, Belgium), which measures the distribution of
exogenous GpC DNA methylation.56 Samples were ampliﬁed in duplicate
using PCR primers designed to exclude either GpC or CpG dinucleotides, in
order to eliminate ampliﬁcation bias (Supplementary Table S5). PCR
products were Sanger sequenced, using 5′- and 3′-end primers to conﬁrm
reads from each end of the product. Each analysis was carried out in
duplicate and the degree of cytosine methylation for each nucleotide
position averaged across replicates. Percentage GpC methylation was
scored in 20% intervals, from which a heatmap was generated.
HPV16 DNA methylation
Five hundred nanograms of genomic DNA were bisulphite-converted
using the EpiTect Bisulﬁte Kit (59104; Qiagen), then desulphonated,
washed and eluted in 40 μl of buffer. PCR ampliﬁcation of HPV16
sequences was carried out using Immolase (Bioline, London, UK) and the
primers listed in Supplementary Table S6. LINE1 ampliﬁcation was also
carried out as a methylation-positive conversion control. Sequencing
primers were designed using PyroQ software (Pyromark MD, Qiagen) and
analysis performed on a Pyromark MD pyrosequencer, using standard
protocols and controls. For each cell line, assays were performed in
duplicate on a minimum of three independently prepared bisulphite-
converted DNA samples.
Figure 9. Working model of the multilayered epigenetic changes that enable high levels of virus gene expression per template following
HPV16 integration. Recruitment of chromatin remodelling enzymes (BRG1/INI1) to the HPV16 genome, possibly through host steroid hormone
nuclear receptors (NR), allows greater accessibility to the virus chromatin of transcription factors (e.g. cJun/AP1) and histone-modifying
enzymes, including MLL1 and SETD1A, which can write the H3K4me1/3 marks. Recruitment of HATs can occur though interactions with
transcription factors (e.g. p300) and histone PTMs, which may allow TIP60 recruitment through its chromodomain. Once acetylation of
histones has occurred, recruitment of CDK9 (the enzymatic component of P-TEFb) is able to activate RNAPII through phosphorylation of Ser2
at the C-terminal domain, leading to stimulation of transcription from the HPV16 early promoter.
Chromatin modiﬁcations determine HPV16 expression
IJ Groves et al
12
Oncogene (2016) 1 – 14 © 2016 Macmillan Publishers Limited
CONFLICT OF INTEREST
The authors declare no conﬂict of interest.
ACKNOWLEDGEMENTS
This work was supported by Cancer Research UK (Programme Grant A13080); the
Medical Research Council; The Pathological Society of Great Britain and Ireland
(ELAK); and the Agency for Science, Technology and Research, Singapore (QYA).
Funding for open access charge: Cancer Research UK and the Medical Research
Council.
REFERENCES
1 Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L et al.
Global burden of human papillomavirus and related diseases. Vaccine 2012; 30:
F12–F23.
2 Jeon S, Allen-Hoffmann BL, Lambert PF. Integration of human papillomavirus type
16 into the human genome correlates with a selective growth advantage of cells.
J Virol 1995; 69: 2989–2997.
3 Groves IJ, Coleman N. Pathogenesis of human papillomavirus-associated mucosal
disease. J Pathol 2015; 235: 527–538.
4 Pett M, Coleman N. Integration of high-risk human papillomavirus: a key event in
cervical carcinogenesis? J Pathol 2007; 212: 356–367.
5 Wentzensen N, Vinokurova S, von Knebel Doeberitz M. Systematic review of
genomic integration sites of human papillomavirus genomes in epithelial
dysplasia and invasive cancer of the female lower genital tract. Cancer Res 2004;
64: 3878–3884.
6 Gray E, Pett MR, Ward D, Winder DM, Stanley MA, Roberts I et al. In vitro pro-
gression of human papillomavirus 16 episome-associated cervical neoplasia dis-
plays fundamental similarities to integrant-associated carcinogenesis. Cancer Res
2010; 70: 4081–4091.
7 Stanley MA, Browne HM, Appleby M, Minson AC. Properties of a non-tumorigenic
human cervical keratinocyte cell line. Int J Cancer 1989; 43: 672–676.
8 Bedell MA, Hudson JB, Golub TR, Turyk ME, Hosken M, Wilbanks GD et al.
Ampliﬁcation of human papillomavirus genomes in vitro is dependent on
epithelial differentiation. J Virol 1991; 65: 2254–2260.
9 Stunkel W, Bernard HU. The chromatin structure of the long control region of
human papillomavirus type 16 represses viral oncoprotein expression. J Virol
1999; 73: 1918–1930.
10 Bernard HU. Regulatory elements in the viral genome. Virology 2013; 445:
197–204.
11 Wooldridge TR, Laimins LA. Regulation of human papillomavirus type 31 gene
expression during the differentiation-dependent life cycle through histone
modiﬁcations and transcription factor binding. Virology 2008; 374: 371–380.
12 Carson A, Khan SA. Characterization of transcription factor binding to human
papillomavirus type 16 DNA during cellular differentiation. J Virol 2006; 80:
4356–4362.
13 del Mar Pena LM, Laimins LA. Differentiation-dependent chromatin rearrange-
ment coincides with activation of human papillomavirus type 31 late gene
expression. J Virol 2001; 75: 10005–10013.
14 Dall KL, Scarpini CG, Roberts I, Winder DM, Stanley MA, Muralidhar B et al.
Characterization of naturally occurring HPV16 integration sites isolated from
cervical keratinocytes under noncompetitive conditions. Cancer Res 2008; 68:
8249–8259.
15 Stoler MH, Rhodes CR, Whitbeck A, Wolinsky SM, Chow LT, Broker TR. Human
papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum Pathol
1992; 23: 117–128.
16 Pett MR, Alazawi WO, Roberts I, Dowen S, Smith DI, Stanley MA et al. Acquisition
of high-level chromosomal instability is associated with integration of human
papillomavirus type 16 in cervical keratinocytes. Cancer Res 2004; 64: 1359–1368.
17 Scarpini CG, Groves IJ, Pett MR, Ward D, Coleman N. Virus transcript levels and cell
growth rates after naturally occurring HPV16 integration events in basal cervical
keratinocytes. J Pathol 2014; 233: 281–293.
18 Bannister AJ, Kouzarides T. Regulation of chromatin by histone modiﬁcations. Cell
Res 2011; 21: 381–395.
19 Wang WM, Wu SY, Lee AY, Chiang CM. Binding site speciﬁcity and factor
redundancy in activator protein-1-driven human papillomavirus chromatin-
dependent transcription. J Biol Chem 2011; 286: 40974–40986.
20 Euskirchen GM, Auerbach RK, Davidov E, Gianoulis TA, Zhong G, Rozowsky J et al.
Diverse roles and interactions of the SWI/SNF chromatin remodeling complex
revealed using global approaches. PLoS Genet 2011; 7: e1002008.
21 Li G, Ruan X, Auerbach RK, Sandhu KS, Zheng M, Wang P et al. Extensive
promoter-centered chromatin interactions provide a topological basis for tran-
scription regulation. Cell 2012; 148: 84–98.
22 Yew CW, Lee P, Chan WK, Lim VK, Tay SK, Tan TM et al. A novel MLL5 isoform that
is essential to activate E6 and E7 transcription in HPV16/18-associated cervical
cancers. Cancer Res 2011; 71: 6696–6707.
23 Dou Y, Milne TA, Ruthenburg AJ, Lee S, Lee JW, Verdine GL et al. Regulation of
MLL1 H3K4 methyltransferase activity by its core components. Nat Struct Mol Biol
2006; 13: 713–719.
24 Wentzensen N, Sun C, Ghosh A, Kinney W, Mirabello L, Wacholder S et al.
Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial
neoplasia grade 3. J Natl Cancer Inst 2012; 104: 1738–1749.
25 McLaughlin-Drubin ME, Crum CP, Munger K. Human papillomavirus E7
oncoprotein induces KDM6A and KDM6B histone demethylase expression
and causes epigenetic reprogramming. Proc Natl Acad Sci USA 2011; 108:
2130–2135.
26 Hyland PL, McDade SS, McCloskey R, Dickson GJ, Arthur K, McCance DJ et al.
Evidence for alteration of EZH2, BMI1, and KDM6A and epigenetic reprogram-
ming in human papillomavirus type 16 E6/E7-expressing keratinocytes. J Virol
2011; 85: 10999–11006.
27 Johannsen E, Lambert PF. Epigenetics of human papillomaviruses. Virology 2013;
445: 205–212.
28 De-Castro Arce J, Gockel-Krzikalla E, Rosl F. Silencing of multi-copy HPV16 by viral
self-methylation and chromatin occlusion: a model for epigenetic virus-host
interaction. Hum Mol Genet 2012; 21: 1693–1705.
29 Johansson C, Jamal Fattah T, Yu H, Nygren J, Mossberg AK, Schwartz S. Acetylation
of intragenic histones on HPV16 correlates with enhanced HPV16 gene expres-
sion. Virology 2015; 482: 244–259.
30 Kruppel U, Muller-Schiffmann A, Baldus SE, Smola-Hess S, Steger G. E2 and the
co-activator p300 can cooperate in activation of the human papillomavirus type
16 early promoter. Virology 2008; 377: 151–159.
31 He H, Luo Y. Brg1 regulates the transcription of human papillomavirus type 18 E6
and E7 genes. Cell Cycle 2012; 11: 617–627.
32 Jha S, Vande Pol S, Banerjee NS, Dutta AB, Chow LT, Dutta A. Destabilization
of TIP60 by human papillomavirus E6 results in attenuation of TIP60-
dependent transcriptional regulation and apoptotic pathway. Mol Cell 2010; 38:
700–711.
33 Smith JA, Haberstroh FS, White EA, Livingston DM, DeCaprio JA, Howley PM.
SMCX and components of the TIP60 complex contribute to E2 regulation of the
HPV E6/E7 promoter. Virology 2014; 468-470: 311–321.
34 Wang Z, Zang C, Cui K, Schones DE, Barski A, Peng W et al. Genome-wide
mapping of HATs and HDACs reveals distinct functions in active and
inactive genes. Cell 2009; 138: 1019–1031.
35 Xu M, Katzenellenbogen RA, Grandori C, Galloway DA. An unbiased in vivo screen
reveals multiple transcription factors that control HPV E6-regulated hTERT in
keratinocytes. Virology 2013; 446: 17–24.
36 Sun Y, Jiang X, Xu Y, Ayrapetov MK, Moreau LA, Whetstine JR et al. Histone H3
methylation links DNA damage detection to activation of the tumour
suppressor Tip60. Nat Cell Biol 2009; 11: 1376–1382.
37 Kim CH, Kim JW, Jang SM, An JH, Seo SB, Choi KH. The chromodomain-containing
histone acetyltransferase TIP60 acts as a code reader, recognizing the epigenetic
codes for initiating transcription. Biosci Biotechnol Biochem 2015; 79: 532–538.
38 Jeong KW, Kim K, Situ AJ, Ulmer TS, An W, Stallcup MR. Recognition of enhancer
element-speciﬁc histone methylation by TIP60 in transcriptional activation. Nat
Struct Mol Biol 2011; 18: 1358–1365.
39 Bogdanovic O, Fernandez-Minan A, Tena JJ, de la Calle-Mustienes E, Hidalgo C,
van Kruysbergen I et al. Dynamics of enhancer chromatin signatures mark the
transition from pluripotency to cell speciﬁcation during embryogenesis. Genome
Res 2012; 22: 2043–2053.
40 Hazzalin CA, Mahadevan LC. Dynamic acetylation of all lysine 4-methylated
histone H3 in the mouse nucleus: analysis at c-fos and c-jun. PLoS Biol 2005; 3:
e393.
41 Wang S, Fischer PM. Cyclin-dependent kinase 9: a key transcriptional regulator
and potential drug target in oncology, virology and cardiology. Trends Pharmacol
Sci 2008; 29: 302–313.
42 Chao SH, Fujinaga K, Marion JE, Taube R, Sausville EA, Senderowicz AM et al.
Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem 2000; 275:
28345–28348.
43 Palermo RD, Webb HM, Gunnell A, West MJ. Regulation of transcription
by the Epstein-Barr virus nuclear antigen EBNA 2. Biochem Soc Trans 2008; 36:
625–628.
44 Zhu Y, Pe'ery T, Peng J, Ramanathan Y, Marshall N, Marshall T et al. Transcription
elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes
Dev 1997; 11: 2622–2632.
45 Hanning JE, Saini HK, Murray MJ, Caffarel MM, van Dongen S, Ward D et al.
Depletion of HPV16 early genes induces autophagy and senescence in a cervical
carcinogenesis model, regardless of viral physical state. J Pathol 2013; 231:
354–366.
Chromatin modiﬁcations determine HPV16 expression
IJ Groves et al
13
© 2016 Macmillan Publishers Limited Oncogene (2016) 1 – 14
46 Coleman N, Greenﬁeld IM, Hare J, Kruger-Gray H, Chain BM, Stanley MA.
Characterization and functional analysis of the expression of intercellular
adhesion molecule-1 in human papillomavirus-related disease of cervical kerati-
nocytes. Am J Pathol 1993; 143: 355–367.
47 Friedl F, Kimura I, Osato T, Ito Y. Studies on a new human cell line (SiHa) derived
from carcinoma of uterus. I. Its establishment and morphology. Proc Soc Exp Biol
Med 1970; 135: 543–545.
48 Coleman N, Stanley MA. Expression of the myelomonocytic antigens CD36 and L1
by keratinocytes in squamous intraepithelial lesions of the cervix. Hum Pathol
1994; 25: 73–79.
49 Hanning JE, Saini HK, Murray MJ, van Dongen S, Davis MP, Barker EM et al. Lack of
correlation between predicted and actual off-target effects of short-interfering
RNAs targeting the human papillomavirus type 16 E7 oncogene. Br J Cancer 2013;
108: 450–460.
50 Hanning JE, Groves IJ, Pett MR, Coleman N. Depletion of polycistronic
transcripts using short interfering RNAs: cDNA synthesis method affects levels of
non-targeted genes determined by quantitative PCR. Virol J 2013; 10: 159.
51 Herdman MT, Pett MR, Roberts I, Alazawi WO, Teschendorff AE, Zhang XY et al.
Interferon-beta treatment of cervical keratinocytes naturally infected with human
papillomavirus 16 episomes promotes rapid reduction in episome numbers and
emergence of latent integrants. Carcinogenesis 2006; 27: 2341–2353.
52 Pfafﬂ MW. A new mathematical model for relative quantiﬁcation in real-time
RT-PCR. Nucleic Acids Res 2001; 29: e45.
53 Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A et al.
Accurate normalization of real-time quantitative RT-PCR data by geometric
averaging of multiple internal control genes. Genome Biol 2002; 3:
RESEARCH0034.
54 Simon JM, Giresi PG, Davis IJ, Lieb JD. Using formaldehyde-assisted isolation of
regulatory elements (FAIRE) to isolate active regulatory DNA. Nat Protoc 2012; 7:
256–267.
55 Groves IJ, Reeves MB, Sinclair JH. Lytic infection of permissive cells with human
cytomegalovirus is regulated by an intrinsic 'pre-immediate-early' repression of
viral gene expression mediated by histone post-translational modiﬁcation. J Gen
Virol 2009; 90: 2364–2374.
56 Kelly TK, Liu Y, Lay FD, Liang G, Berman BP, Jones PA. Genome-wide mapping of
nucleosome positioning and DNA methylation within individual DNA molecules.
Genome Res 2012; 22: 2497–2506.
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the Creative Commons
license, users will need to obtain permission from the license holder to reproduce the
material. To view a copy of this license, visit http://creativecommons.org/licenses/
by/4.0/
Supplementary Information accompanies this paper on the Oncogene website (http://www.nature.com/onc)
Chromatin modiﬁcations determine HPV16 expression
IJ Groves et al
14
Oncogene (2016) 1 – 14 © 2016 Macmillan Publishers Limited
